The Endothelin Axis Stimulates the Expression of Pro-Inflammatory Cytokines and Pro-Migratory Molecules in Breast Cancer

REFERENCES

• Traina, T.A.; Rugo, H.S.; Dickler, M. Bevacizumab for advanced breast cancer. Hematol Oncol Clin North Am 2007, 21(2), 303–319.
   PubMed Web of Science ®Google Scholar
• DeNardo, D.G.; Coussens, L.M. Inflammation and breast cancer. Balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression. Breast Cancer Res 2007, 9(4), 212.
   PubMed Web of Science ®Google Scholar
• Mantovani, A.; Marchesi, F.; Porta, C.; Sica, A.; Allavena, P. Inflammation and cancer: breast cancer as a prototype. Breast 2007, 16(Suppl 2), S27–S33.
   Google Scholar
• Benoy, I.H.; Salgado, R.; Van Dam, P.; Geboers, K.; Van Marck, E.; Scharpe, S.; Vermeulen, P.B.; Dirix, L.Y. Increased serum interleukin-8 in patients with early and metastatic breast cancer correlates with early dissemination and survival. Clin Cancer Res 2004, 10(21), 7157–7162.
   PubMed Web of Science ®Google Scholar
• Il’yasova, D.; Colbert, L.H.; Harris, T.B.; Newman, A.B.; Bauer, D.C.; Satterfield, S.; Kritchevsky, S.B. Circulating levels of inflammatory markers and cancer risk in the health aging and body composition cohort. Cancer Epidemiol Biomarkers Prev 2005, 14(10), 2413–2418.
   PubMed Web of Science ®Google Scholar
• Angelo, L.S.; Kurzrock, R. Vascular endothelial growth factor and its relationship to inflammatory mediators. Clin Cancer Res 2007, 13(10), 2825–2830.
   PubMed Web of Science ®Google Scholar
• Radisky, E.S.; Radisky, D.C. Stromal induction of breast cancer: inflammation and invasion. Rev Endocr Metab Disord 2007, 8(3), 279–287.
   PubMed Web of Science ®Google Scholar
• Guise, T.A.; Mohammad, K.S. Endothelins in bone cancer metastases. Cancer Treat Res 2004, 118, 197–212.
   PubMedGoogle Scholar
• Knowles, J.; Loizidou, M.; Taylor, I. Endothelin-1 and angiogenesis in cancer. Curr Vasc Pharmacol 2005, 3(4), 309–314.
   PubMedGoogle Scholar
• Grimshaw, M.J. Endothelins and hypoxia-inducible factor in cancer. Endocr Relat Cancer 2007, 14(2), 233–244.
   PubMed Web of Science ®Google Scholar
• Herrmann, E.; Bogemann, M.; Bierer, S.; Eltze, E.; Hertle, L.; Wulfing, C. The endothelin axis in urologic tumors: mechanisms of tumor biology and therapeutic implications. Expert Rev Anticancer Ther 2006, 6(1), 73–81.
   PubMed Web of Science ®Google Scholar
• Bagnato, A.; Spinella, F.; Rosano, L. The endothelin axis in cancer: the promise and the challenges of molecularly targeted therapy. Can J Physiol Pharmacol 2008, 86(8), 473–484.
   PubMed Web of Science ®Google Scholar
• Lalich, M.; McNeel, D.G.; Wilding, G.; Liu, G. Endothelin receptor antagonists in cancer therapy. Cancer Invest 2007, 25(8), 785–794.
   PubMed Web of Science ®Google Scholar
• Bagnato, A.; Catt, K.J. Endothelins as autocrine regulators of tumor cell growth. Trends Endocrinol Metab 1998, 9(9), 378–383.
   PubMed Web of Science ®Google Scholar
• Wulfing, P.; Diallo, R.; Kersting, C.; Wulfing, C.; Poremba, C.; Greb, R.R.; Bocker, W.; Kiesel, L. Endothelin-1, endothelin-A- and endothelin-B-receptor expression in preinvasive and invasive breast disease. Oncol Rep 2004, 11(4), 791–796.
   PubMed Web of Science ®Google Scholar
• Kojima, K.; Nihei, Z. Expression of endothelin-1 immunoreactivity in breast cancer. Surg Oncol 1995, 4(6), 309–315.
   PubMed Web of Science ®Google Scholar
• Kaur, B.; Khwaja, F.W.; Severson, E.A.; Matheny, S.L.; Brat, D.J.; Van Meir, E.G. Hypoxia and the hypoxia-inducible-factor pathway in glioma growth and angiogenesis. Neuro-oncol 2005, 7(2), 134–153.
   PubMed Web of Science ®Google Scholar
• Sampaio, A.L.; Rae, G.A.; Henriques, M.G. Effects of endothelin ETA receptor antagonism on granulocyte and lymphocyte accumulation in LPS-induced inflammation. J Leukoc Biol 2004, 76(1), 210–216.
   PubMed Web of Science ®Google Scholar
• Grimshaw, M.J.; Hagemann, T.; Ayhan, A.; Gillett, C.E.; Binder, C.; Balkwill, F.R. A role for endothelin-2 and its receptors in breast tumor cell invasion. Cancer Res 2004, 64(7), 2461–2468.
   PubMed Web of Science ®Google Scholar
• Grimshaw, M.J.; Wilson, J.L.; Balkwill, F.R. Endothelin-2 is a macrophage chemoattractant: implications for macrophage distribution in tumors. Eur J Immunol 2002, 32(9), 2393–2400.
   PubMed Web of Science ®Google Scholar
• Smollich, M.; Gotte, M.; Kersting, C.; Fischgrabe, J.; Kiesel, L.; Wulfing, P. Selective ET(A)R antagonist atrasentan inhibits hypoxia-induced breast cancer cell invasion. Breast Cancer Res Treat 2008, 108(2), 175–182.
   PubMed Web of Science ®Google Scholar
• Wulfing, P.; Gotte, M.; Sonntag, B.; Kersting, C.; Schmidt, H.; Wulfing, C.; Buerger, H.; Greb, R.; Bocker, W.; Kiesel, L. Overexpression of endothelin-A-receptor in breast cancer: regulation by estradiol and cobalt-chloride induced hypoxia. Int J Oncol 2005, 26(4), 951–960.
   PubMed Web of Science ®Google Scholar
• Grimshaw, M.J. Endothelins in breast tumour cell invasion. Cancer Lett 2005, 222(2), 129–138.
   PubMed Web of Science ®Google Scholar
• Wilson, J.L.; Burchell, J.; Grimshaw, M.J. Endothelins induce CCR7 expression by breast tumor cells via endothelin receptor A and hypoxia-inducible factor-1. Cancer Res 2006, 66(24), 11802–11807.
   PubMed Web of Science ®Google Scholar
• Dréau, D.; Karaa, A.; Culberson, C.; Wyan, H.; McKillop, I.H.; Clemens, M.G. Bosentan inhibits tumor vascularization and bone metastasis in an immunocompetent skin-fold chamber model of breast carcinoma cell metastasis. Clin Exp Metastasis 2006, 23, 41–53.
   PubMed Web of Science ®Google Scholar
• Yin, J.J.; Mohammad, K.S.; Kakonen, S.M.; Harris, S.; Wu-Wong, J.R.; Wessale, J.L.; Padley, R.J.; Garrett, I.R.; Chirgwin, J.M.; Guise, T.A. A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases. Proc Natl Acad Sci USA 2003, 100(19), 10954–10959.
   PubMed Web of Science ®Google Scholar
• Wulfing, P.; Tio, J.; Kersting, C.; Sonntag, B.; Buerger, H.; Wulfing, C.; Euler, U.; Boecker, W.; Tulusan, A.H.; Kiesel, L. Expression of endothelin-A-receptor predicts unfavourable response to neoadjuvant chemotherapy in locally advanced breast cancer. Br J Cancer 2004, 91(3), 434–440.
   PubMed Web of Science ®Google Scholar
• Rai, A.; Rajeshkumar, N.V.; Gulati, A. Effect of the ET(B) receptor agonist, IRL-1620, on paclitaxel plasma pharmacokinetics of breast tumor rats. Exp Biol Med (Maywood) 2006, 231(6), 1120–1122.
   PubMed Web of Science ®Google Scholar
• Yamashita, J.; Ogawa, M.; Nomura, K.; Matsuo, S.; Inada, K.; Yamashita, S.; Nakashima, Y.; Saishoji, T.; Takano, S.; Fujita, S. Interleukin 6 stimulates the production of immunoreactive endothelin 1 in human breast cancer cells. Cancer Res 1993, 53(3), 464–467.
   PubMed Web of Science ®Google Scholar
• Li, C.Y.; Shan, S.; Huang, Q.; Braun, R.D.; Lanzen, J.; Hu, K.; Lin, P.; Dewhirst, M.W. Initial stages of tumor cell-induced angiogenesis: evaluation via skin window chambers in rodent models. J Natl Cancer Inst 2000, 92(2), 143–147.
   PubMed Web of Science ®Google Scholar
• Aslakson, C.J.; Miller, F.R. Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res 1992, 52(6), 1399–1405.
   PubMed Web of Science ®Google Scholar
• Inokuchi, M.; Ninomiya, I.; Tsugawa, K.; Terada, I.; Miwa, K. Quantitative evaluation of metastases in axillary lymph nodes of breast cancer. Br J Cancer 2003, 89(9), 1750–1756.
   PubMed Web of Science ®Google Scholar
• Pfaffl, M.W. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001, 29(9), e45.
   PubMed Web of Science ®Google Scholar
• Lebret, S.C.; Newgreen, D.F.; Thompson, E.W.; Ackland, M.L. Induction of epithelial to mesenchymal transition in PMC42-LA human breast carcinoma cells by carcinoma-associated fibroblast secreted factors. Breast Cancer Res 2007, 9(1), R19.
   PubMedGoogle Scholar
• Salani, D.; Taraboletti, G.; Rosano, L. Di Castro, V.; Borsotti, P.; Giavazzi, R.; Bagnato, A. Endothelin-1 induces an angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. Am J Pathol 2000, 157(5), 1703–1711.
   PubMed Web of Science ®Google Scholar
• Liang, Y.; Eid, M.A.; El Etreby, F.; Lewis, R.W.; Kumar, M.V. Mifepristone-induced secretion of transforming growth factor beta1-induced apoptosis in prostate cancer cells. Int J Oncol 2002, 21(6), 1259–1267.
   PubMed Web of Science ®Google Scholar
• Liang, C.C.; Park, A.Y.; Guan, J.L. In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro. Nat Protoc 2007, 2(2), 329–333.
   PubMed Web of Science ®Google Scholar
• Bonacci, G.R.; Caceres, L.C.; Sanchez, M.C.; Chiabrando, G.A. Activated alpha(2)-macroglobulin induces cell proliferation and mitogen-activated protein kinase activation by LRP-1 in the J774 macrophage-derived cell line. Arch Biochem Biophys 2007, 460(1), 100–106.
   PubMed Web of Science ®Google Scholar
• Huang, G.; Hu, Z.; Li, M.; Cui, Y.; Li, Y.; Guo, L.; Jiang, W.; Lu, S.H. ECRG2 inhibits cancer cell migration, invasion and metastasis through the down-regulation of uPA/plasmin activity. Carcinogenesis 2007, 28(11), 2274–2281.
   PubMed Web of Science ®Google Scholar
• Akhtari, M.; Mansuri, J.; Newman, K.A.; Guise, T.M.; Seth, P. Biology of breast cancer bone metastasis. Cancer Biol Ther 2008, 7(1), 3–9.
   PubMed Web of Science ®Google Scholar
• Spyridopoulos, I.; Brogi, E.; Kearney, M.; Sullivan, A.B.; Cetrulo, C.; Isner, J.M.; Losordo, D.W. Vascular endothelial growth factor inhibits endothelial cell apoptosis induced by tumor necrosis factor-alpha: balance between growth and death signals. J Mol Cell Cardiol 1997, 29(5), 1321–1330.
   PubMed Web of Science ®Google Scholar
• Bagnato, A.; Rosano, L. The endothelin axis in cancer. Int J Biochem Cell Biol 2008, 40(8), 1443–1451.
   PubMed Web of Science ®Google Scholar
• Binder, C.; Hagemann, T.; Sperling, S.; Schulz, M.; Pukrop, T.; Grimshaw, M.J.; Ehrenreich, H. Stromal endothelin B receptor-deficiency inhibits breast cancer growth and metastasis. Mol Cancer Ther 2009, 8(8), 2452–2460.
   PubMed Web of Science ®Google Scholar
• Berger, Y.; Bernasconi, C.C.; Juillerat-Jeanneret, L. Targeting the endothelin axis in human melanoma: combination of endothelin receptor antagonism and alkylating agents. Exp Biol Med (Maywood) 2006, 231(6), 1111–1119.
   PubMed Web of Science ®Google Scholar
• Smollich, M.; Wulfing, P. The endothelin axis: a novel target for pharmacotherapy of female malignancies. Curr Vasc Pharmacol 2007, 5(3), 239–248.
   PubMed Web of Science ®Google Scholar
• Lissoni, P.; Malugani, F.; Bonfanti, A.; Bucovec, R.; Secondino, S.; Brivio, F.; Ferrari-Bravo, A.; Ferrante, R.; Vigore, L.; Rovelli F.; Mandalá, M.; Viviani, S.; Fumagalli, L.; Gardani, G. S. Abnormally enhanced blood concentrations of vascular endothelial growth factor (VEGF) in metastatic cancer patients and their relation to circulating dendritic cells, IL-12 and endothelin-1. J Biol Regul Homeost Agents 2001, 15(2), 140–144.
   PubMed Web of Science ®Google Scholar
• Ruetten, H.; Thiemermann, C. Endothelin-1 stimulates the biosynthesis of tumour necrosis factor in macrophages: ET-receptors, signal transduction and inhibition by dexamethasone. J Physiol Pharmacol 1997, 48(4), 675–688.
   PubMed Web of Science ®Google Scholar
• Le Brun, G.; Aubin, P.; Soliman, H.; Ropiquet, F.; Villette, J.M.; Berthon, P.; Creminon, C.; Cussenot, O.; Fiet, J. Upregulation of endothelin 1 and its precursor by IL-1beta, TNF-alpha, and TGF-beta in the PC3 human prostate cancer cell line. Cytokine 1999, 11(2), 157–162.
   PubMed Web of Science ®Google Scholar
• Coulombe, M.; Battistini, B.; Stankova, J.; Pouliot, P.; Bissonnette, E.Y. Endothelins regulate mediator production of rat tissue-cultured mucosal mast cells. Up-regulation of Th1 and inhibition of Th2 cytokines. J Leukoc Biol 2002, 71(5), 829–836.
   PubMed Web of Science ®Google Scholar
• Mencarelli, M.; Pecorelli, A.; Carbotti, P.; Valacchi, G.; Grasso, G.; Muscettola, M. Endothelin receptor A expression in human inflammatory cells. Regul Pept 2009, 158, 1–5.
   PubMed Web of Science ®Google Scholar
• Lambert, L.A.; Whyteside, A.R.; Turner, A.J.; Usmani, B.A. Isoforms of endothelin-converting enzyme-1 (ECE-1) have opposing effects on prostate cancer cell invasion. Br J Cancer 2008, 99(7), 1114–1120.
   PubMed Web of Science ®Google Scholar
• Stankova, J.; D’Orleans-Juste, P.; Rola-Pleszczynski, M. ET-1 induces IL-6 gene expression in human umbilical vein endothelial cells: synergistic effect of IL-1. Am J Physiol 1996, 271(4 Pt 1), C1073–C1078.
   PubMed Web of Science ®Google Scholar
• Murri, A.A.; Hilmy, M.; Bell, J.; Wilson, C.; McNicol, A.M.; Lannigan, A.; Doughty, J.C.; McMillan, D.C. The relationship between the systemic inflammatory response, tumour proliferative activity, T-lymphocytic and macrophage infiltration, microvessel density and survival in patients with primary operable breast cancer. Br J Cancer 2008, 99(7), 1013–1019.
   PubMed Web of Science ®Google Scholar
• Lin, E.Y.; Li, J.F.; Gnatovskiy, L.; Deng, Y.; Zhu, L.; Grzesik, D.A.; Qian, H.; Xue, X.N.; Pollard, J.W. Macrophages regulate the angiogenic switch in a mouse model of breast cancer. Cancer Res 2006, 66(23), 11238–11246.
   PubMed Web of Science ®Google Scholar
• Okazaki, M.; Yoshimura, K.; Uchida, G.; Harii, K. Correlation between age and the secretions of melanocyte-stimulating cytokines in cultured keratinocytes and fibroblasts. Br J Dermatol 2005, 153(Suppl 2), 23–29.
   PubMedGoogle Scholar
• Maestroni, G.J. Therapeutic potential of melatonin in immunodeficiency states, viral diseases, and cancer. Adv Exp Med Biol 1999, 467, 217–226.
   PubMed Web of Science ®Google Scholar
• Lyon, D.E.; McCain, N.L.; Walter, J.; Schubert, C. Cytokine comparisons between women with breast cancer and women with a negative breast biopsy. Nurs Res 2008, 57(1), 51–58.
   PubMed Web of Science ®Google Scholar
• Ma, X.J.; Wang, Z.; Ryan, P.D.; Isakoff, S.J.; Barmettler, A.; Fuller, A.; Muir, B.; Mohapatra, G.; Salunga, R.; Tuggle, J.T. and others. A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell 2004, 5(6), 607–616.
   PubMed Web of Science ®Google Scholar
• Nam, J.S.; Terabe, M.; Kang, M.J.; Chae, H.; Voong, N.; Yang, Y.A.; Laurence, A.; Michalowska, A.; Mamura, M.; Lonning S. and others. Transforming growth factor beta subverts the immune system into directly promoting tumor growth through interleukin-17. Cancer Res 2008, 68(10), 3915–3923.
   PubMed Web of Science ®Google Scholar
• Shimozato, O.; Ugai, S.; Chiyo, M.; Takenobu, H.; Nagakawa, H.; Wada, A.; Kawamura, K.; Yamamoto, H.; Tagawa, M. The secreted form of the p40 subunit of interleukin (IL)-12 inhibits IL-23 functions and abrogates IL-23-mediated antitumour effects. Immunology 2006, 117(1), 22–28.
   PubMed Web of Science ®Google Scholar
• Hoeve, M.A.; Savage, N.D.; de Boer, T.; Langenberg, D.M.; de Waal Malefyt, R.; Ottenhoff, T.H.; Verreck, F.A. Divergent effects of IL-12 and IL-23 on the production of IL-17 by human T cells. Eur J Immunol 2006, 36(3), 661–670.
   PubMed Web of Science ®Google Scholar